company background image
DNLI logo

Denali Therapeutics NasdaqGS:DNLI Stock Report

Last Price

US$18.26

Market Cap

US$2.6b

7D

-4.1%

1Y

-28.5%

Updated

15 Apr, 2024

Data

Company Financials +

Denali Therapeutics Inc.

NasdaqGS:DNLI Stock Report

Market Cap: US$2.6b

DNLI Stock Overview

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States.

DNLI fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Denali Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Denali Therapeutics
Historical stock prices
Current Share PriceUS$18.26
52 Week HighUS$33.31
52 Week LowUS$15.45
Beta1.33
1 Month Change-9.29%
3 Month Change-0.60%
1 Year Change-28.50%
3 Year Change-65.61%
5 Year Change-26.49%
Change since IPO-14.87%

Recent News & Updates

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Recent updates

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Feb 21
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Jan 26
Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Nov 20
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Oct 09
Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Aug 22
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

May 02
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Mar 04
Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Feb 06
Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Nov 09
These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Denali Therapeutics proposes $250M stock offering; shares down 6% post market

Oct 18

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Oct 12
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Oct 10

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Jun 08
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Denali Therapeutics Inc. (NASDAQ:DNLI) Analysts Just Slashed This Year's Estimates

Mar 07
Denali Therapeutics Inc. (NASDAQ:DNLI) Analysts Just Slashed This Year's Estimates

Denali Therapeutics: 2021 Was Mostly Bad Luck And Trouble

Feb 25

Are Investors Undervaluing Denali Therapeutics Inc. (NASDAQ:DNLI) By 28%?

Feb 14
Are Investors Undervaluing Denali Therapeutics Inc. (NASDAQ:DNLI) By 28%?

Denali Therapeutics: Another Near-Term Capital Gain Prospect Market-Makers See As Underpriced

Sep 10

Shareholder Returns

DNLIUS BiotechsUS Market
7D-4.1%-2.8%-1.7%
1Y-28.5%-0.2%22.4%

Return vs Industry: DNLI underperformed the US Biotechs industry which returned -0.2% over the past year.

Return vs Market: DNLI underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is DNLI's price volatile compared to industry and market?
DNLI volatility
DNLI Average Weekly Movement13.7%
Biotechs Industry Average Movement11.6%
Market Average Movement6.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: DNLI's share price has been volatile over the past 3 months.

Volatility Over Time: DNLI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013445Ryan Wattswww.denalitherapeutics.com

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.

Denali Therapeutics Inc. Fundamentals Summary

How do Denali Therapeutics's earnings and revenue compare to its market cap?
DNLI fundamental statistics
Market capUS$2.60b
Earnings (TTM)-US$145.22m
Revenue (TTM)US$330.53m

7.9x

P/S Ratio

-17.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DNLI income statement (TTM)
RevenueUS$330.53m
Cost of RevenueUS$423.88m
Gross Profit-US$93.34m
Other ExpensesUS$51.88m
Earnings-US$145.22m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.02
Gross Margin-28.24%
Net Profit Margin-43.94%
Debt/Equity Ratio0%

How did DNLI perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.